HC Wainwright Issues Pessimistic Outlook for IONS Earnings

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS – Free Report) – Research analysts at HC Wainwright cut their FY2026 earnings per share estimates for Ionis Pharmaceuticals in a research note issued on Tuesday, November 10th. HC Wainwright analyst M. Kapoor now anticipates that the company will earn ($3.44) per share for the year, down from their prior estimate of ($3.41). HC Wainwright currently has a “Buy” rating and a $70.00 target price on the stock. The consensus estimate for Ionis Pharmaceuticals’ current full-year earnings is ($3.48) per share. HC Wainwright also issued estimates for Ionis Pharmaceuticals’ Q4 2026 earnings at ($1.52) EPS, Q1 2027 earnings at ($1.09) EPS, Q2 2027 earnings at ($0.90) EPS, Q3 2027 earnings at ($0.10) EPS and FY2027 earnings at ($1.94) EPS.

IONS has been the subject of a number of other reports. UBS Group began coverage on shares of Ionis Pharmaceuticals in a report on Thursday, October 15th. They issued a “buy” rating and a $88.00 target price for the company. Citigroup reaffirmed a “buy” rating on shares of Ionis Pharmaceuticals in a research report on Wednesday, October 21st. Oppenheimer cut their price target on shares of Ionis Pharmaceuticals from $85.00 to $70.00 and set an “outperform” rating on the stock in a report on Tuesday, November 10th. Canaccord Genuity Group decreased their price objective on shares of Ionis Pharmaceuticals from $95.00 to $85.00 and set a “buy” rating for the company in a research report on Tuesday, September 8th. Finally, JPMorgan Chase & Co. lowered their price objective on shares of Ionis Pharmaceuticals from $76.00 to $70.00 and set an “overweight” rating for the company in a research note on Tuesday, September 22nd. Nineteen investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $75.00.

Check Out Our Latest Analysis on IONS

Ionis Pharmaceuticals Stock Performance

Shares of NASDAQ:IONS opened at $26.58 on Friday. The company has a debt-to-equity ratio of 3.42, a quick ratio of 5.36 and a current ratio of 5.43. The firm has a market cap of $4.43 billion, a PE ratio of -8.01 and a beta of 0.43. The firm’s 50 day simple moving average is $40.76 and its 200-day simple moving average is $63.17. Ionis Pharmaceuticals has a one year low of $26.53 and a one year high of $86.74.

Ionis Pharmaceuticals (NASDAQ:IONS – Get Free Report) last released its quarterly earnings data on Monday, November 9th. The company reported ($0.66) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.23) by $0.57. Ionis Pharmaceuticals had a negative return on equity of 120.62% and a negative net margin of 56.98%. The firm had revenue of $242.72 million during the quarter, compared to analyst estimates of $178.17 million. During the same quarter in the prior year, the company posted ($0.80) earnings per share. The business’s quarterly revenue was up 54.8% compared to the same quarter last year.

Institutional Trading of Ionis Pharmaceuticals

Institutional investors and hedge funds have recently made changes to their positions in the company. Virtu Financial LLC purchased a new position in shares of Ionis Pharmaceuticals during the 3rd quarter valued at approximately $483,000. Allworth Financial LP boosted its holdings in Ionis Pharmaceuticals by 537.6% in the third quarter. Allworth Financial LP now owns 3,290 shares of the company’s stock worth $147,000 after purchasing an additional 2,774 shares during the period. Quantitative Investment Management LLC bought a new position in shares of Ionis Pharmaceuticals in the 3rd quarter worth about $423,000. Quarry LP grew its position in shares of Ionis Pharmaceuticals by 6,796.6% during the 3rd quarter. Quarry LP now owns 2,000 shares of the company’s stock valued at $89,000 after buying an additional 1,971 shares during the last quarter. Finally, Aquatic Capital Management LLC raised its stake in Ionis Pharmaceuticals by 39.9% during the third quarter. Aquatic Capital Management LLC now owns 59,561 shares of the company’s stock worth $2,659,000 after acquiring an additional 16,980 shares during the period. 93.86% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Ionis Pharmaceuticals

In other news, Director Michael R. Hayden purchased 5,000 shares of the company’s stock in a transaction dated Tuesday, November 10th. The shares were acquired at an average cost of $29.64 per share, for a total transaction of $148,200.00. Following the completion of the purchase, the director directly owned 27,000 shares in the company, valued at $800,280. The trade was a 22.73% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Shannon L. Devers sold 1,357 shares of the business’s stock in a transaction on Friday, October 16th. The stock was sold at an average price of $43.54, for a total transaction of $59,083.78. Following the sale, the executive vice president owned 17,811 shares in the company, valued at $775,490.94. The trade was a 7.08% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 1.81% of the stock is owned by corporate insiders.

Key Headlines Impacting Ionis Pharmaceuticals

These are some of the IONS headlines that stood out recently:

  • Positive Sentiment: HC Wainwright maintained its Buy rating and $70 price target, despite lowering its earnings forecasts. Ionis analyst estimates
  • Negative Sentiment: HC Wainwright lowered its earnings estimates across several periods. Its FY2027 loss estimate widened to $1.94 per share from $1.25, and it also cut estimates for Q4 2026 and Q1–Q3 2027. The downward revisions could reinforce concerns about Ionis’s path to profitability. Ionis analyst estimates
  • Negative Sentiment: Guggenheim also cut its price target for Ionis, adding to the bearish analyst news; the report provided here does not specify the new target. Ionis Pharmaceuticals stock price target cut by Guggenheim

Ionis Pharmaceuticals Company Profile

(Get Free Report)

Ionis Pharmaceuticals is a biotechnology company that discovers and develops RNA-targeted medicines, with a focus on antisense oligonucleotides. Its medicines are designed to act on RNA and change the production of proteins linked to disease. The company’s research and development programs span neurological, cardiovascular, metabolic and rare diseases. Ionis has developed medicines that it commercializes itself and products advanced or marketed with pharmaceutical partners. Its medicines and partnered products include treatments for conditions such as spinal muscular atrophy and transthyretin amyloidosis.

Further Reading

Earnings History and Estimates for Ionis Pharmaceuticals (NASDAQ:IONS)

Receive News & Ratings for Ionis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.